[go: up one dir, main page]

ECSP10010499A - Proceso para la preparación de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4-benzodioxin-2il)metil-sulfamida - Google Patents

Proceso para la preparación de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4-benzodioxin-2il)metil-sulfamida

Info

Publication number
ECSP10010499A
ECSP10010499A EC2010010499A ECSP10010499A ECSP10010499A EC SP10010499 A ECSP10010499 A EC SP10010499A EC 2010010499 A EC2010010499 A EC 2010010499A EC SP10010499 A ECSP10010499 A EC SP10010499A EC SP10010499 A ECSP10010499 A EC SP10010499A
Authority
EC
Ecuador
Prior art keywords
preparation
sulfamates
benzofused
heteroarilo
benzodioxin
Prior art date
Application number
EC2010010499A
Other languages
English (en)
Inventor
Ahmed F Abdel-Magid
Steven J Mehrman
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP10010499A publication Critical patent/ECSP10010499A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/04—Seven-membered rings not condensed with other rings
    • C07D321/08—1,4-Dioxepines; Hydrogenated 1,4-dioxepines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se dirige a un proceso para la preparación de sulfamatos de heteroarilo benzofusionado, útiles para el tratamiento de epilepsia y trastornos relacionados, de conformidad con la Fórmula (IA) y con un compuesto cristalino de la Fórmula (I-S).Proceso para la preparación de un compuesto de Fórmula (IA).
EC2010010499A 2008-03-26 2010-09-24 Proceso para la preparación de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4-benzodioxin-2il)metil-sulfamida ECSP10010499A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/058233 WO2009120191A1 (en) 2008-03-26 2008-03-26 Process for the preparation of benzo-fused heteroaryl sulfamates and crystalline form of n- ( ( (2s) -6-chloro-2,3-dihydro-l,4-benzodioxin-2-yl) methyl-sulfamide

Publications (1)

Publication Number Publication Date
ECSP10010499A true ECSP10010499A (es) 2010-10-30

Family

ID=40030223

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010499A ECSP10010499A (es) 2008-03-26 2010-09-24 Proceso para la preparación de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4-benzodioxin-2il)metil-sulfamida

Country Status (14)

Country Link
EP (1) EP2280950A1 (es)
JP (1) JP2011515464A (es)
KR (1) KR20100126535A (es)
CN (1) CN101981019A (es)
AU (1) AU2008353491A1 (es)
BR (1) BRPI0822454A2 (es)
CA (1) CA2719624A1 (es)
CR (1) CR11761A (es)
EA (1) EA201071120A1 (es)
EC (1) ECSP10010499A (es)
IL (1) IL208222A0 (es)
MX (1) MX2010010595A (es)
WO (1) WO2009120191A1 (es)
ZA (1) ZA201007611B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP2008545650A (ja) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
WO2007137167A2 (en) 2006-05-19 2007-11-29 Janssen Pharmaceutica N.V. Co-therapy for the treatment of epilepsy
PE20110060A1 (es) * 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN107954906B (zh) * 2017-11-24 2020-10-16 西北师范大学 一种芳基磺酰叔胺类化合物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
ES2310366T3 (es) * 2004-08-24 2009-01-01 Janssen Pharmaceutica Nv Nuevos derivados de heteroaril sulfonamida benzo-condensada utiles como agentes anticonvulsivos.
TW200738669A (en) * 2006-02-22 2007-10-16 Janssen Pharmaceutica Nv Crystalline forms of N-(benzo[b]thien-3-ylmethyl)-sulfamide

Also Published As

Publication number Publication date
EA201071120A1 (ru) 2011-06-30
MX2010010595A (es) 2010-10-25
CA2719624A1 (en) 2009-10-01
CN101981019A (zh) 2011-02-23
ZA201007611B (en) 2012-04-25
BRPI0822454A2 (pt) 2015-06-16
EP2280950A1 (en) 2011-02-09
WO2009120191A1 (en) 2009-10-01
JP2011515464A (ja) 2011-05-19
IL208222A0 (en) 2010-12-30
AU2008353491A1 (en) 2009-10-01
CR11761A (es) 2011-07-06
KR20100126535A (ko) 2010-12-01

Similar Documents

Publication Publication Date Title
ECSP10010499A (es) Proceso para la preparación de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4-benzodioxin-2il)metil-sulfamida
ECSP10010498A (es) Procesos para la preparación de derivados de heteroarilo benzofusionados
EP2397459A4 (en) METHOD FOR PRODUCING A PHENYLACETAMIDE COMPOUND
JP2013540893A5 (es)
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
EP2508655A4 (en) Method of producing silicon carbide monocrystals
TN2010000539A1 (en) Salts and polymorphs of a tetracylcline compound
BRPI0905147A8 (pt) processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável
AR061311A1 (es) Procesos para preparar clorhidrato de cinacalcet y formas polimorficas del mismo
UY31803A (es) Compuesto cristalino
CR20160465A (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)
CL2008002532A1 (es) Procedimiento de sintesis de un derivado de pirido-[2,1-a]isoquinolina; formas cristalinas de dichos compuestos; y su uso para tratar diabetes, diabetes mellitus, trastorno de la intolerancia a la glucosa.
EA201200740A1 (ru) Способ пиролиза углеводов
EA201170481A1 (ru) Сокристаллы
EP2441514A4 (en) AMMOXIDATION CATALYST AND METHOD FOR PRODUCING A NITRILE COMPOUND THEREWITH
CL2012003371A1 (es) Compuestos intermediarios de la síntesis de agomelatina; y el procedimiento de obtención de agomelatina a partir de dichos compuestos intermediarios
BR112012009611A2 (pt) ''processo para a preparação de um composto de fómula (i)''
BRPI1007718A2 (pt) processo para a produção de cristais de cianeto de sódio
GT200900215A (es) Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina.
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
CL2012000270A1 (es) Procedimiento de preparacion de ivabradina y de sus sales de adicion por formacion del anillo benzoacepino; y los compuestos intermediarios considerados en el procedimiento.
CO6390054A2 (es) Formas cristalinas de un compuesto 3-carboxipropil-aminotetralina
EP2428501A4 (en) DIARYL-IODONIUM SALT MIXTURE AND MANUFACTURING METHOD AND MANUFACTURING METHOD FOR A DIARYL-IODONIUM COMPOUND
MA35362B1 (fr) Nouvelle forme de cristal
CO6290652A2 (es) Proceso para la preparcion de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4benzodioxin-2il)metil-sulfamida